Kydes Pharmaceuticals
KYDES Pharmaceuticals LLC is a privately owned pharmaceutical company based in Maryland, USA, with a vision to design scientifically sound and cost-effective pharmaceutical products using state-of-the-art knowledge and technologies. The company aims to develop therapeutic advancements for diseases with unmet medical needs, producing high-quality medicines for export to developing countries and the domestic market. KYDES focuses on innovative prescription pharmaceuticals addressing large unmet medical needs, with a long-term goal of becoming a respected source of breakthrough pharmaceutical products, capturing significant market share, and achieving high market valuations.
Industries
Nr. of Employees
small (1-50)
Kydes Pharmaceuticals
University of Maryland Baltimore County Research & Technology Park, 1450 South Rolling Rd, Halethorpe, MD 21227
Products
Topical NSAID formulation for localized joint pain (development-stage)
Topical analgesic formulation intended to address joint pain and inflammation with reduced systemic toxicity; development and patenting activities reported, with regulatory work for OTC classification outside the US.
Locally intensive gynecologic therapies (development-stage)
Therapies developed for treatment of malignant and non-malignant proliferative gynecological disorders using local delivery approaches.
Topical vaginal microbicide for HIV prevention (development-stage)
Combination mucosal product administered vaginally intended to reduce viral integration and replication as a prophylactic microbicide; alternative dosage forms considered to improve mucosal coverage and user acceptance.
Therapy for persistent HPV infection and cervical dysplasia (development-stage)
Locally delivered therapeutic approach adapted from microbicide technology for treatment of persistent HPV infection and cervical dysplasia.
Intravenous anti-adherent adjuvant therapy (development-stage)
Intravenous formulation with anti-adherent properties intended as an adjuvant for drug-resistant malaria, leukemia, sickle cell crisis, chemotherapy-induced micro-thrombosis, and certain resistant infections.
Oral abuse-deterrent opioid formulations (development-stage)
Oral formulations designed to minimize tampering and reduce overdose potential through physical and formulation-based abuse-deterrent features.
Topical NSAID formulation for localized joint pain (development-stage)
Topical analgesic formulation intended to address joint pain and inflammation with reduced systemic toxicity; development and patenting activities reported, with regulatory work for OTC classification outside the US.
Locally intensive gynecologic therapies (development-stage)
Therapies developed for treatment of malignant and non-malignant proliferative gynecological disorders using local delivery approaches.
Topical vaginal microbicide for HIV prevention (development-stage)
Combination mucosal product administered vaginally intended to reduce viral integration and replication as a prophylactic microbicide; alternative dosage forms considered to improve mucosal coverage and user acceptance.
Therapy for persistent HPV infection and cervical dysplasia (development-stage)
Locally delivered therapeutic approach adapted from microbicide technology for treatment of persistent HPV infection and cervical dysplasia.
Intravenous anti-adherent adjuvant therapy (development-stage)
Intravenous formulation with anti-adherent properties intended as an adjuvant for drug-resistant malaria, leukemia, sickle cell crisis, chemotherapy-induced micro-thrombosis, and certain resistant infections.
Oral abuse-deterrent opioid formulations (development-stage)
Oral formulations designed to minimize tampering and reduce overdose potential through physical and formulation-based abuse-deterrent features.
Services
Formulation design and development services across dosage forms for preclinical and clinical stages.
Transfer of formulation and process data to manufacturing partners and support for scale-up to CGMP production.
Formulation design and development services across dosage forms for preclinical and clinical stages.
Transfer of formulation and process data to manufacturing partners and support for scale-up to CGMP production.
Expertise Areas
- Formulation development across dosage forms
- Vaginal and mucosal drug delivery
- Topical and localized therapy development
- Abuse-deterrent formulation strategies
Key Technologies
- Topical/transdermal formulation
- Vaginal/mucosal delivery systems (gels, films, rings, tablets)
- Oral abuse-deterrent formulation techniques
- Intravenous anti-adherent formulation